AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03838562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation with virtual reality
Description: Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group.
Study NCT03838562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard optokinetic stimulator or dynamic visual surround
Description: Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group.
Study NCT01601808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally once a day, continuously throughout the study
Study NCT01601808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caprelsa (vandetanib)
Description: Orally once a daily, continuously throughout the study.
Study NCT04532918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.
Study NCT04532918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.
Study NCT04532918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: The subjects will receive single oral dose of soft capsule cyclosporine 600 mg on Day 1 of treatment period 2 under fasted condition.
Study NCT04532918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: The subjects will receive single oral dose of film coated tablets rifampicin 600 mg on Day 1 of treatment period 3 under fasted condition.
Study NCT01082367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TOBI
Description: TOBI (tobramycin inhaled solution)
Study NCT01082367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOBI
Description: TOBI (tobramycin inhaled solution)
Study NCT01082367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01082367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04574388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open label placebo
Description: open label placebo pill
Study NCT04151095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR Exercise Training
Description: Participants will complete exercise training on a recumbent bike placed on a 45 degree incline (BFR).
Study NCT01820780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultations specialized to J7 and J14
Description: Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
Study NCT01820780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone calls in 6 months and 12 months
Study NCT01820780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phone calls in 6 months and 12 months
Study NCT01820780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natriuretic peptides levels at 6 months
Study NCT01820780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natriuretic peptides levels at 6 months
Study NCT01820780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation with the general doctor or the cardiologist to J30 with blood results
Study NCT01820780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consultation with the general doctor or the cardiologist to J30 with blood results
Study NCT02931214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1359
Study NCT02931214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04134611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid injection
Description: Injection of Hyaluronic acid in knees of those who has degenerative changes after arthroscopic treatment of lateral patellar compression syndrome
Study NCT04134611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No injection of Hyaluronic acid
Description: No injection of Hyaluronic acid was done
Study NCT01950780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
Study NCT02880137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microsphere
Description: Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20 MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.
Study NCT02880137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RTMPE
Description: Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
Study NCT02775136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000 recording
Study NCT03416803 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study NCT03195036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based ECD services
Description: Health facilities will be randomized to intervention and control groups. The clients at clinics assigned to the intervention group will receive Home-based Early Childhood Development (ECD+) program. The clients at clinics assigned to the control group will not receive the Early Childhood Development (ECD) program.
Study NCT01624441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV
Study NCT01624441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin Hydrochloride
Description: Given IV
Study NCT01624441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03928314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle
Study NCT03928314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle
Study NCT02844517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
Study NCT00104091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-38
Description: TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
Study NCT04131049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI calculated by CC (CHGI)
Description: This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
Study NCT04131049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI calculated by CC (CLGI)
Description: This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
Study NCT04131049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI calculated by FII (FHGI)
Description: This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
Study NCT04131049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI calculated by FII (FLGI)
Description: This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
Study NCT03437915 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NIBB: accuboost
Description: 28.5 Gy delivered in 5 daily fractions
Study NCT03437915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial mastectomy
Description: 4-12 weeks post NIBB
Study NCT01550276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas.
Study NCT01550276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal.
Study NCT01550276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation.
Study NCT01550276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position.
Study NCT01211561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium, selenomethionine
Description: Patients will receive one 200 ug pill of Selenomethionine
Study NCT01211561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients will be given one 200 ug placebo pill each day for 6 months
Study NCT02005744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: CKD-501 0.5mg, PO(per oral), once
Study NCT00797719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-op RT +/- chemotherapy
Description: Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
Study NCT00615576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933
Description: SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.
Study NCT00615576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
Study NCT03792516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate ointment 40%
Description: artesunate formulated as an ointment to be applied topically to the vulva
Study NCT01440764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Study NCT01440764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study NCT02005406 — intervention group
Intervention type: DEVICE
Intervention: Experimental group and control groupl
Description: JET
Study NCT02773693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy-Cognitive Only (CPT)
Description: Twice weekly CPT over 6 weeks.
Study NCT02773693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)
Description: Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
Study NCT02773693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuation Cognitive Processing Therapy-Cognitive Only (CPT)
Description: Once weekly continuation CPT over 6 weeks.
Study NCT00687713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: 150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
Study NCT00687713 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04372316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylcobalamin
Description: methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks
Study NCT01873313 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine
Study NCT03976570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Occupational therapy to children with subthreshold attention deficit hyperactivity disorder
Study NCT00486018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab injection 0.3 mg
Description: Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Study NCT00486018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab injection 0.5 mg
Description: Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Study NCT00486018 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
Study NCT00554775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
Study NCT00554775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
Study NCT02328222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESW group
Description: CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
Study NCT04149886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac ganglion plexus ablation(cardioneuroablation)
Description: Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.
Study NCT04149886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker implantation
Description: DDD permanent pacemaker will be implanted in the paticipants.
Study NCT04149886 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Permanent pacemaker implantation
Description: DDD permanent pacemaker will be implanted in the paticipants.
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet orally administered under fasting
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet orally administered under fasting
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablet orally administered under fasting
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodon bitartrate-acetaminophen arm 1
Description: Tablet orally administered under fasted conditions
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocodon bitartrate-acetaminophen arm 1
Description: Tablet orally administered under fasted conditions
Study NCT02630836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-MT-OSTEO-BETA
Description: XCEL-MT-OSTEO-BETA followed by endomedullary nailing
Study NCT02630836 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment
Description: Isolated endomedullary nailing
Study NCT02630836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Isolated endomedullary nailing
Study NCT01700049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib (150 mg PO daily)
Description: Biopsies will be performed on all participants at baseline, week 12 and week 24.
Study NCT01425333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for ovarian endometrioma
Description: Patients undergoing surgery for ovarian endometrioma
Study NCT02857738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987519
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study NCT02857738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 Control
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study NCT00306150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trasylol (Aprotinin, BAYA0128)
Description: Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
Study NCT00306150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is used according to the description of Arm 1
Study NCT00000569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone
Description: 1200 micrograms of triamcinolone in daily divided doses
Study NCT00000569 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00903448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec OTC (omeprazole-magnesium)
Description: Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast